ABBV

Abbvie Inc

• The Motley Fool·9h ago

  3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

• Seeking Alpha·10h ago

  Going Deeper On Disc Medicine

• Dow Jones·1d ago

  Biogen Inc. Stock Falls 2.9%, Underperforms Peers

• TipRanks·1d ago

  AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress

• NASDAQ·1d ago

  See Which Recent 13F Filers Hold ABBV

• Benzinga·1d ago

  Clinical Trial Results Show Extended Benefits for REGENXBIO Retinal Treatments

• Barron‘s·2d ago

  What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

• The Motley Fool·2d ago

  How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?

• Seeking Alpha·2d ago

  Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data

• The Motley Fool·2d ago

  My 2 Favorite Dividend Kings to Buy Right Now

• Simply Wall St·2d ago

  How AbbVie’s New Rapid-Onset Boey Toxin Could Reshape Aesthetics Demand for AbbVie (ABBV) Investors

• Benzinga·4d ago

  Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today

• Seeking Alpha·4d ago

  Where To Invest Now In AI, Biotech, Small Caps, And Gold

• NASDAQ·4d ago

  AbbVie's Boey Gets EU Approval For Treatment Of Moderate-To-Severe Glabellar Lines

• Simply Wall St·4d ago

  AbbVie (ABBV) Boey Approval Puts Its Growth Story And Valuation Back In Focus